Erste Asset Management GmbH Lowers Stock Position in Agilent Technologies, Inc. $A

Key Points

• Erste Asset Management GmbH reduced its holdings in Agilent Technologies by 9.4%, owning 103,272 shares valued at approximately $12 million post-sale.
• Institutional activity included significant increases from Quantbot Technologies (up 423%) and smaller boosts from RWA Wealth Partners and Korea Investment CORP in the first quarter.
• Analysts have mixed ratings on Agilent, with price targets ranging from $125 to $155 and a consensus rating of "Moderate Buy."

Erste Asset Management GmbH cut its holdings in Agilent Technologies, Inc. (NYSE:A - Free Report) by 9.4% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 103,272 shares of the medical research company's stock after selling 10,712 shares during the period. Erste Asset Management GmbH's holdings in Agilent Technologies were worth $12,081,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in A. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Agilent Technologies by 13.5% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company's stock worth $4,279,000 after purchasing an additional 4,362 shares during the period. Assenagon Asset Management S.A. boosted its stake in shares of Agilent Technologies by 8.3% during the 1st quarter. Assenagon Asset Management S.A. now owns 30,827 shares of the medical research company's stock worth $3,606,000 after purchasing an additional 2,371 shares during the period. Alps Advisors Inc. boosted its stake in shares of Agilent Technologies by 29.5% during the 1st quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company's stock worth $1,563,000 after purchasing an additional 3,040 shares during the period. D.A. Davidson & CO. boosted its stake in shares of Agilent Technologies by 30.4% during the 1st quarter. D.A. Davidson & CO. now owns 9,474 shares of the medical research company's stock worth $1,108,000 after purchasing an additional 2,207 shares during the period. Finally, LGT Capital Partners LTD. boosted its stake in shares of Agilent Technologies by 7.6% during the 1st quarter. LGT Capital Partners LTD. now owns 768,252 shares of the medical research company's stock worth $89,870,000 after purchasing an additional 54,302 shares during the period.

Insider Buying and Selling at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 1,508 shares of the company's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total value of $177,099.52. Following the completion of the sale, the chief executive officer owned 37,448 shares of the company's stock, valued at approximately $4,397,893.12. This represents a 3.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Wall Street Analyst Weigh In

A has been the subject of a number of recent analyst reports. Barclays lifted their price target on shares of Agilent Technologies from $115.00 to $125.00 and gave the stock an "equal weight" rating in a research note on Tuesday, June 24th. TD Cowen lifted their price target on shares of Agilent Technologies to $150.00 and gave the stock a "buy" rating in a research note on Thursday, May 29th. Leerink Partners lifted their price target on shares of Agilent Technologies to $135.00 and gave the stock a "buy" rating in a research note on Friday, May 30th. JPMorgan Chase & Co. lowered their price objective on shares of Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating for the company in a research report on Thursday, May 29th. Finally, Robert W. Baird dropped their target price on shares of Agilent Technologies from $159.00 to $140.00 and set an "outperform" rating on the stock in a research note on Thursday, May 22nd. Seven equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $139.77.

Agilent Technologies Trading Up 3.7%

A stock traded up $4.3420 during mid-day trading on Friday, reaching $121.4920. The company had a trading volume of 1,290,972 shares, compared to its average volume of 1,284,543. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.09 and a quick ratio of 1.60. The company has a market capitalization of $34.51 billion, a PE ratio of 30.00, a price-to-earnings-growth ratio of 3.69 and a beta of 1.22. The firm has a 50 day moving average of $117.88 and a 200 day moving average of $117.26. Agilent Technologies, Inc. has a 12 month low of $96.43 and a 12 month high of $153.84.

Agilent Technologies (NYSE:A - Get Free Report) last issued its earnings results on Wednesday, May 28th. The medical research company reported $1.31 EPS for the quarter, topping analysts' consensus estimates of $1.26 by $0.05. The business had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.63 billion. Agilent Technologies had a net margin of 17.59% and a return on equity of 25.92%. The company's revenue for the quarter was up 6.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.22 EPS. Agilent Technologies has set its FY 2025 guidance at 5.540-5.610 EPS. Q3 2025 guidance at 1.350-1.370 EPS. On average, equities analysts predict that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.